Teligent Company Profile (NASDAQ:TLGT)

About Teligent (NASDAQ:TLGT)

Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.

Industry, Sector and Symbol:

Sector: Medical
Industry: Pharmaceuticals - NEC
Sub-Industry: N/A
Symbol: NASDAQ:TLGT
CUSIP: N/A
Web: www.teligent.com

Capitalization:

Market Cap: $452.42 million
Outstanding Shares: 53,226,000

Average Prices:

50 Day Moving Avg: $8.88
200 Day Moving Avg: $7.95
52 Week Range: $5.75 - $9.54

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: 21.09
P/E Growth: 3.330

Sales & Book Value:

Annual Revenue: $71.12 million
Price / Sales: 6.31
Book Value: $1.10 per share
Price / Book: 7.70

Profitability:

EBIDTA: $9.15 million
Net Margins: -14.35%
Return on Equity: 5.43%
Return on Assets: 1.74%

Debt:

Debt-to-Equity Ratio: 1.95%
Current Ratio: 5.62%
Quick Ratio: 4.83%

Misc:

Average Volume: 324,224 shs.
Beta: 1.63
Short Ratio: 20.2

Frequently Asked Questions for Teligent (NASDAQ:TLGT)

What is Teligent's stock symbol?

Teligent trades on the NASDAQ under the ticker symbol "TLGT."

How were Teligent's earnings last quarter?

Teligent, Inc. (NASDAQ:TLGT) issued its earnings results on Tuesday, March, 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $17.90 million for the quarter, compared to analysts' expectations of $17.97 million. Teligent had a negative net margin of 14.35% and a positive return on equity of 5.43%. The business's revenue was up 36.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.02) earnings per share. View Teligent's Earnings History.

When will Teligent make its next earnings announcement?

Teligent is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Teligent.

Where is Teligent's stock going? Where will Teligent's stock price be in 2017?

2 brokerages have issued 12-month price targets for Teligent's shares. Their predictions range from $9.00 to $10.00. On average, they expect Teligent's stock price to reach $9.50 in the next year. View Analyst Ratings for Teligent.

Who are some of Teligent's key competitors?

Some companies that are related to Teligent include Amphastar Pharmaceuticals (AMPH), Lannett Co (LCI), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Aceto Corporation (ACET), Collegium Pharmaceutical (COLL), Aquinox Pharmaceuticals (AQXP), Tetraphase Pharmaceuticals (TTPH), Corium International (CORI), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), BioDelivery Sciences International (BDSI), Adamis Pharmaceuticals Corporation (ADMP), Aralez Pharmaceuticals (ARLZ), Intellipharmaceutics International (IPCI), Concordia International Corp. (CXRX), Diurnal Group PLC (DNL) and Innocoll Holdings (INNL).

Who are Teligent's key executives?

Teligent's management team includes the folowing people:

Jason Grenfell-Gardner, President, Chief Executive Officer, Director
Jenniffer L. Collins, Chief Financial Officer
Stephen Richardson, Chief Scientific Officer
Carole S. Ben-Maimon M.D., Director
John E. Celentano, Director
Steven Hubrig Koehler, Director
Narendra N. Borkar, Independent Director
Bhaskar Michael Chaudhuri Ph.D., Independent Director

Who owns Teligent stock?

Teligent's stock is owned by many different of institutional and retail investors. Top institutional investors include AMI Asset Management Corp (2.66%), Sanders Morris Harris LLC (1.79%), Summit Creek Advisors LLC (1.29%), Atria Investments LLC (0.06%), Aperio Group LLC (0.05%) and Round Table Services LLC (0.03%). Company insiders that own Teligent stock include James C Gale and Jason Grenfell-Gardner. View Institutional Ownership Trends for Teligent.

Who sold Teligent stock? Who is selling Teligent stock?

Teligent's stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Summit Creek Advisors LLC, Atria Investments LLC, AMI Asset Management Corp and Round Table Services LLC. View Insider Buying and Selling for Teligent.

Who bought Teligent stock? Who is buying Teligent stock?

Teligent's stock was purchased by a variety of institutional investors in the last quarter, including Aperio Group LLC. Company insiders that have bought Teligent stock in the last two years include James C Gale and Jason Grenfell-Gardner. View Insider Buying and Selling for Teligent.

How do I buy Teligent stock?

Shares of Teligent can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teligent's stock price today?

One share of Teligent stock can currently be purchased for approximately $8.44.

MarketBeat Community Rating for Teligent (NASDAQ TLGT)

Community Ranking:		2.1 out of 5 ( )
Outperform Votes:		50 (Vote Outperform)
Underperform Votes:		69 (Vote Underperform)
Total Votes:		119

MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Teligent (NASDAQ:TLGT) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Hold Rating, 1 Buy Rating
Consensus Rating:	Buy (Score: 2.50)
Consensus Price Target:	$9.50 (12.63% upside)

Analysts' Ratings History for Teligent (NASDAQ:TLGT)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
7/17/2017	Deutsche Bank AG	Reiterated Rating	Hold	$8.00 -> $9.00	High
10/28/2016	Roth Capital	Set Price Target	Buy	$10.00	N/A
6/29/2016	JMP Securities	Initiated Coverage	Hold		N/A
6/22/2016	Raymond James Financial, Inc.	Initiated Coverage	Strong-Buy	$11.00	N/A
4/26/2016	Oppenheimer Holdings, Inc.	Reiterated Rating	Hold		N/A

(Data available from 7/22/2015 forward)

Earnings History for Teligent (NASDAQ:TLGT)

Earnings by Quarter for Teligent (NASDAQ:TLGT)

Earnings History by Quarter for Teligent (NASDAQ TLGT)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/26/2017		$0.03					N/A
3/7/2017	Q4 2016		$0.01	$17.97 million	$17.90 million	View	Listen
10/27/2016	Q3	$0.00	$0.01	$16.90 million	$16.20 million	View	Listen
7/28/2016	Q2	($0.02)	$0.02	$16.03 million	$17.14 million	View	Listen
4/28/2016	Q116	($0.03)	$0.02	$14.33 million	$15.70 million	View	N/A
3/9/2016	Q415	($0.02)	($0.02)	$11.69 million	$13.10 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Teligent (NASDAQ:TLGT)

2017 EPS Consensus Estimate: $0.14

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	1	$0.03	$0.03	$0.03
Q2 2017	1	$0.02	$0.02	$0.02
Q3 2017	1	$0.04	$0.04	$0.04
Q4 2017	1	$0.05	$0.05	$0.05

(Data provided by Zacks Investment Research)

Dividend History for Teligent (NASDAQ:TLGT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Teligent (NASDAQ:TLGT)

Insider Ownership Percentage: 22.60%
Institutional Ownership Percentage: 63.57%

Institutional Ownership by Quarter for Teligent (NASDAQ:TLGT)

Insider Trades by Quarter for Teligent (NASDAQ:TLGT)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
3/11/2016	James C Gale	Director	Buy	15,000	$4.91	$73,650.00
3/11/2016	Jason Grenfell-Gardner	CEO	Buy	10,500	$4.82	$50,610.00

(Data available from 1/1/2013 forward)

Headline Trends for Teligent (NASDAQ:TLGT) Latest Headlines for Teligent (NASDAQ:TLGT)

Source:

Date	Headline
	Teligent (TLGT) Receives FDA Approval for Erythromycin Topical Gel USP, 2% www.streetinsider.com - July 22 at 9:39 AM
	Teligent, Inc. Announces FDA Approval Of Erythromycin Topical Gel USP, 2% finance.yahoo.com - July 22 at 9:39 AM
	Teligent Shares Rise on FDA Approval for Erythromycin Topical Gel finance.yahoo.com - July 22 at 9:39 AM
	Zacks: Analysts Expect Teligent, Inc. (NASDAQ:TLGT) Will Post Quarterly Sales of $20.20 Million www.americanbankingnews.com - July 22 at 8:24 AM
	Analysts Expect Teligent, Inc. (TLGT) to Post $0.03 Earnings Per Share www.americanbankingnews.com - July 20 at 10:15 PM
	Teligent, Inc. (TLGT) Scheduled to Post Quarterly Earnings on Wednesday www.americanbankingnews.com - July 19 at 8:53 AM
	Teligent, Inc. breached its 50 day moving average in a Bullish Manner : TLGT-US : July 17, 2017 finance.yahoo.com - July 18 at 9:04 AM
	Deutsche Bank AG Increases Teligent, Inc. (NASDAQ:TLGT) Price Target to $9.00 www.americanbankingnews.com - July 17 at 5:58 PM
	Collegium Pharmaceutical (COLL) vs. Teligent (TLGT) Critical Review www.americanbankingnews.com - July 14 at 10:29 PM
	ETFs with exposure to Teligent, Inc. : July 11, 2017 finance.yahoo.com - July 12 at 8:11 AM
	Teligent, Inc. (TLGT) Downgraded by Zacks Investment Research to "Sell" www.americanbankingnews.com - July 6 at 2:00 PM
	Teligent, Inc. (TLGT) Expected to Announce Quarterly Sales of $20.70 Million www.americanbankingnews.com - June 28 at 10:12 AM
	Analysts Expect Teligent, Inc. (TLGT) to Announce $0.03 EPS www.americanbankingnews.com - June 26 at 8:38 PM
	ETFs with exposure to Teligent, Inc. : June 14, 2017 finance.yahoo.com - June 15 at 2:23 AM
	Analyzing Lannett Co (LCI) and Teligent (TLGT) www.americanbankingnews.com - June 12 at 12:06 AM
	Head to Head Comparison: Teligent (TLGT) & Theravance Biopharma (TBPH) www.americanbankingnews.com - June 9 at 7:43 AM
	Brokerages Expect Teligent Inc (TLGT) Will Post Quarterly Sales of $20.70 Million www.americanbankingnews.com - June 2 at 1:10 PM
	ETFs with exposure to Teligent, Inc. : May 31, 2017 finance.yahoo.com - May 31 at 10:12 PM
	Brokerages Expect Teligent Inc (TLGT) Will Post Earnings of $0.03 Per Share www.americanbankingnews.com - May 31 at 4:22 PM
	Teligent (TLGT) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow seekingalpha.com - May 24 at 8:50 AM
	ETFs with exposure to Teligent, Inc. : May 16, 2017 finance.yahoo.com - May 16 at 8:11 PM
	Teligent, Inc. To Present At Bank Of America Merrill Lynch Healthcare Conference Taking Place May 16, 2017 finance.yahoo.com - May 16 at 8:46 AM
	Teligent, Inc. :TLGT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 15, 2017 finance.yahoo.com - May 15 at 7:24 PM
	Zacks: Analysts Expect Teligent Inc (TLGT) to Post $0.03 Earnings Per Share www.americanbankingnews.com - May 5 at 4:19 PM
	Teligent (TLGT) Receives News Impact Score of 0.10 www.americanbankingnews.com - May 3 at 8:36 PM
	ETFs with exposure to Teligent, Inc. : May 3, 2017 finance.yahoo.com - May 3 at 6:27 PM
	Teligent's (TLGT) CEO Jason Grenfell-Gardner on Q1 2017 Results - Earnings Call Transcript seekingalpha.com - May 3 at 10:19 AM
	Teligent, Inc. To Present At Deutsche Bank 42nd Annual Health Care Conference On May 3, 2017 finance.yahoo.com - May 3 at 10:19 AM
	Teligent tops 1Q profit forecasts marketbeat.com - May 2 at 7:18 PM
	Teligent, Inc. Announces First Quarter 2017 Results finance.yahoo.com - May 2 at 6:13 PM
	Investor Network: Teligent, Inc. to Host Earnings Call finance.yahoo.com - May 2 at 8:54 AM
	The 3 Best Pharmaceutical Stocks to Buy in 2017 finance.yahoo.com - April 29 at 3:52 PM
	Teligent (TLGT) Getting Somewhat Negative News Coverage, Study Finds www.americanbankingnews.com - April 29 at 11:15 AM
	Teligent (TLGT) Given Daily Coverage Optimism Rating of -0.06 www.americanbankingnews.com - April 25 at 6:31 PM
	Teligent, Inc. Appoints Martin Wilson To General Counsel finance.yahoo.com - April 25 at 9:18 AM
	Teligent (TLGT) Given Coverage Optimism Score of 0.22 www.americanbankingnews.com - April 21 at 10:52 PM
	Teligent, Inc. To Hold Conference Call For 1st Quarter 2017 Results finance.yahoo.com - April 21 at 11:48 AM
	ETFs with exposure to Teligent, Inc. : April 20, 2017 finance.yahoo.com - April 20 at 10:17 PM
	Teligent (TLGT) Receiving Somewhat Critical Media Coverage, Study Finds www.americanbankingnews.com - April 18 at 10:00 AM
	$21.03 Million in Sales Expected for Teligent Inc (TLGT) This Quarter www.americanbankingnews.com - April 16 at 8:28 AM
	Teligent (TLGT) Earns Daily Coverage Optimism Rating of -0.08 www.americanbankingnews.com - April 15 at 1:48 PM
	$0.02 Earnings Per Share Expected for Teligent Inc (TLGT) This Quarter www.americanbankingnews.com - April 14 at 6:20 PM
	Teligent Inc (TLGT) Sees Significant Decrease in Short Interest www.americanbankingnews.com - April 13 at 11:10 AM
	Teligent Inc (TLGT) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - April 11 at 9:06 AM
	Teligent, Inc. To Present At Oppenheimer 27th Annual Healthcare Conference On March 22, 2017 finance.yahoo.com - March 22 at 8:11 PM
	TELIGENT, INC. Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements and Exhibits biz.yahoo.com - March 18 at 2:08 AM
	TELIGENT, INC. Files SEC form 10-K, Annual Report biz.yahoo.com - March 15 at 9:46 PM
	Teligent, Inc. To Present At 29th Annual ROTH Conference On March 13, 2017 finance.yahoo.com - March 13 at 7:50 PM
	Teligent, Inc. (Nasdaq: TLGT) to Ring The Nasdaq Stock Market Closing Bell - Nasdaq www.nasdaq.com - March 9 at 8:13 PM
	Teligent (TLGT) Recieves FDA Approval for Clobetasol Propionate Gel, 0.05% www.streetinsider.com - March 8 at 10:42 PM